TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CellaVision AB ( (SE:CEVI) ) has issued an update.
CellaVision has achieved CE marking approval for its Bone Marrow Aspirate Application under the EU In Vitro Diagnostic Regulation as a Class C product, marking a significant milestone. This approval allows laboratories to automate and standardize bone marrow aspirate examinations, enhancing efficiency and reducing workload in diagnosing hematologic conditions, thus strengthening CellaVision’s position in the medical technology industry.
The most recent analyst rating on (SE:CEVI) stock is a Hold with a SEK174.00 price target. To see the full list of analyst forecasts on CellaVision AB stock, see the SE:CEVI Stock Forecast page.
More about CellaVision AB
CellaVision is a global medical technology company specializing in developing and selling systems for routine analysis of blood and other body fluids, aiding in swift and accurate disease diagnoses. The company focuses on replacing manual laboratory work with automated solutions, leveraging expertise in sample preparation, image analysis, artificial intelligence, and automated microscopy. CellaVision operates through global partners and local market support organizations in over 40 countries, with a registered office in Lund, Sweden, and is listed on the Nasdaq Stockholm Mid Cap list.
YTD Price Performance: -27.27%
Average Trading Volume: 27,437
Technical Sentiment Signal: Sell
Current Market Cap: SEK3.73B
Learn more about CEVI stock on TipRanks’ Stock Analysis page.